A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer.
(2023) In Cancers 15(15).- Abstract
Lung cancer represents the leading cause of annual cancer-related deaths worldwide, accounting for 12.9%. The available treatment options for patients who experience disease progression remain limited. Targeted therapeutic approaches are promising but further understanding of the role of genetic alterations in tumorigenesis is imperative. The MET gene has garnered great interest in this regard. The aim of this systematic review was to analyze the findings from multiple studies to provide a comprehensive and unbiased summary of the evidence. A systematic search was conducted in the reputable scientific databases Embase and PubMed, leading to the inclusion of twenty-two articles, following the PRISMA guidelines, elucidating the biological... (More)
Lung cancer represents the leading cause of annual cancer-related deaths worldwide, accounting for 12.9%. The available treatment options for patients who experience disease progression remain limited. Targeted therapeutic approaches are promising but further understanding of the role of genetic alterations in tumorigenesis is imperative. The MET gene has garnered great interest in this regard. The aim of this systematic review was to analyze the findings from multiple studies to provide a comprehensive and unbiased summary of the evidence. A systematic search was conducted in the reputable scientific databases Embase and PubMed, leading to the inclusion of twenty-two articles, following the PRISMA guidelines, elucidating the biological role of MET in lung cancer and targeted therapies. The systematic review was registered in PROSPERO with registration ID: CRD42023437714. MET mutations were detected in 7.6-11.0% of cases while MET gene amplification was observed in 3.9-22.0%. Six studies showed favorable treatment outcomes utilizing MET inhibitors compared to standard treatment or placebo, with increases in PFS and OS ranging from 0.9 to 12.4 and 7.2 to 24.2 months, respectively, and one study reporting an increase in ORR by 17.3%. Furthermore, patients with a higher mutational burden may derive greater benefit from treatment with MET tyrosine kinase inhibitors (TKIs) than those with a lower mutational burden. Conversely, two studies reported no beneficial effect from adjunctive treatment with a MET targeted therapy. Given these findings, there is an urgent need to identify effective therapeutic strategies specifically targeting the MET gene in lung cancer patients.
(Less)
- author
- Bodén, Embla LU ; Sveréus, Fanny LU ; Olm, Franziska LU and Lindstedt, Sandra LU
- organization
-
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- LUCC: Lund University Cancer Centre
- WCMM-Wallenberg Centre for Molecular Medicine
- Experimental oncology (research group)
- Kidney cancer research group (research group)
- Acoustofluidics group (research group)
- Clinical and experimental lung transplantation (research group)
- NPWT technology (research group)
- DCD transplantation of lungs (research group)
- publishing date
- 2023-07-27
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancers
- volume
- 15
- issue
- 15
- article number
- 3827
- publisher
- MDPI AG
- external identifiers
-
- scopus:85167712711
- pmid:37568643
- ISSN
- 2072-6694
- DOI
- 10.3390/cancers15153827
- language
- English
- LU publication?
- yes
- id
- 3a9e2b1d-1d93-4a58-835d-7e72712d4d04
- date added to LUP
- 2023-08-19 14:38:16
- date last changed
- 2024-04-20 01:02:02
@article{3a9e2b1d-1d93-4a58-835d-7e72712d4d04, abstract = {{<p>Lung cancer represents the leading cause of annual cancer-related deaths worldwide, accounting for 12.9%. The available treatment options for patients who experience disease progression remain limited. Targeted therapeutic approaches are promising but further understanding of the role of genetic alterations in tumorigenesis is imperative. The MET gene has garnered great interest in this regard. The aim of this systematic review was to analyze the findings from multiple studies to provide a comprehensive and unbiased summary of the evidence. A systematic search was conducted in the reputable scientific databases Embase and PubMed, leading to the inclusion of twenty-two articles, following the PRISMA guidelines, elucidating the biological role of MET in lung cancer and targeted therapies. The systematic review was registered in PROSPERO with registration ID: CRD42023437714. MET mutations were detected in 7.6-11.0% of cases while MET gene amplification was observed in 3.9-22.0%. Six studies showed favorable treatment outcomes utilizing MET inhibitors compared to standard treatment or placebo, with increases in PFS and OS ranging from 0.9 to 12.4 and 7.2 to 24.2 months, respectively, and one study reporting an increase in ORR by 17.3%. Furthermore, patients with a higher mutational burden may derive greater benefit from treatment with MET tyrosine kinase inhibitors (TKIs) than those with a lower mutational burden. Conversely, two studies reported no beneficial effect from adjunctive treatment with a MET targeted therapy. Given these findings, there is an urgent need to identify effective therapeutic strategies specifically targeting the MET gene in lung cancer patients. </p>}}, author = {{Bodén, Embla and Sveréus, Fanny and Olm, Franziska and Lindstedt, Sandra}}, issn = {{2072-6694}}, language = {{eng}}, month = {{07}}, number = {{15}}, publisher = {{MDPI AG}}, series = {{Cancers}}, title = {{A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer.}}, url = {{http://dx.doi.org/10.3390/cancers15153827}}, doi = {{10.3390/cancers15153827}}, volume = {{15}}, year = {{2023}}, }